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• Relatively rare amongst children
• Majority occur sporadically and are non-hereditary
• Despite this, carcinoid tumours may also be 
associated with hereditary syndromes
• Most endocrine tumours in children 
o Clinically benign
o Low grade malignancies
• NETS
o Known for late diagnoses
• Liver or bone metastases
• Multi year history of symptoms before malignancy identified
o Few reports in children
• At least 10% of children have metastatic disease at presentation
Distribution of NETS in children 
and young adults <30 years
Tumour type Percentage of NET in this age group
Bronchial NET 28
Medullary carcinoma of the breast 18
Appendiceal NET 18
Colon and rectal NET 9
Jejunal and ileal NET 5
Small cell carcinoma (ovary) 5
Unknown primary NET 5
Pancreatic and gastric NET * 4
Medullary carcinoma thyroid * 4







o Peak incidence between 9 -12 years of age 
• Nearly 10% occur in children
• 10% of these are malignant
• Paranganglioma
o Extra adrenal in origin
o Parasympathetic nervous system
Screening
• MEN 1 & 2 and VHL
o Autosomal dominant
• Only one mutation in one pair of genes is needed to cause the 
condition
• 50% chance of having a boy or a girl with the same condition
o Most commonly present in early adulthood and onwards
o Can now target individuals at risk
o Genetic screening allows the children from affected families who have 
NOT inherited the mutation
• Reassured
• Avoid regular clinical monitoring
• Issues re: Informed consent, counselling and confidentiality

Family trees
• Biological relationships between family
members
• Any medical conditions
o Reveal patterns of inheritance
o Assesses likelihood of genetic diseases in relatives
o Individuals can then be offered targeted surveillance
Including children
• Builds rapport with patients
o Develop trust, to ask questions




o 90% of MEN1 patients
• Pituitary tumours
o 30% of MEN1 patients
• Pancreatic Islet cell 
tumours
o 75% of MEN1 patients
• Carcinoid tumours




MEN 1 screening in 
children
• Children of an 
identified MEN1 patient
o Screened genetically initially













o Child with a known MEN2a 
gene change
• Total thryoidectomy before 
age of 5yrs
o Newly diagnosed adults




• 24hr urine collections
MEN 2b
• Thyroid gland tumours
• Phaeochromocytomas
• Benign lumps on the lips,
in the mouth and throughout 
the gut
o Children
• More likely to have feeding 
problems, bowel problems
o Present with FTT
MEN 2 screening 
• Screened genetically
o MTC assoc with MEN2b
• Can occur in first year of 
life
o MEN2b – age 1yr




















• Helps regulate BP by 
controlling how much salt 
is retained in the body
• Glucocorticoids
o CORTISOL
• The body’s natural steroid, 3 
main functions:
o Helps control the blood 
sugar level
o Helps the body deal 
with stress
o Helps to control BP and 
blood circulation













o Muscle glycogen breakdown
o Blood flow to muscle
o Respiration
o Noradrenaline
• Similar effects to adrenaline, as well as maintains BP
o Dopamine




• Usually benign, can be 
malignant
• Excretes excess 
catecholamines
• Uncommon cause of ­
BP \ can easily be 
missed
• We have occasional 
bursts of cats when we 
are upset or stressed
o Those with phaeos have 
it all the time
Phaeochromocytoma
• Only present in 10% of VHLs
• French study in the 90s
o Phaeos were the first 
manifestation of VHL disease 
in 51% of pts
o Only manifestation for up to 
age 21 yrs, or even indefinitely
• Easy to miss the diagnosis
• Usually arise in the adrenals, 
may also originate in 










• May be incorrectly 
attributed to anxiety or 
depression
• Can cause life 
threatening conditions
o Hypertensive crisis
o Mets - Stroke
o Cardiac failure - MI
Von Hippel-Lindau disease
• Chromosome 3
• Tumour suppressor 
gene
• Can identify the gene
o Pre-symptomatic screening
• Autosomal dominant
o Each child of an affected 
individual has a 1 in 2 chance 
(50%) to inherit the gene 
alteration
• Children referred
o Fellow adult endocrine teams 
managing in their 
affectedparent
Von Hippel Lindau disease
• Incidence
o 1 in 40,000
o Average age of presentation
• 26 yrs of age
• Haemangioblastomas










o Now leading cause of death 
amongst VHL patients




o Analysis of the index case is key 
to identifying  further members 
of the family at risk
o Can be done from age 5yrs
• Enable clinical screening
Reduction in morbidity compared 
to their parents
Case study
• Male child Tom
• DOB 10.11.01
• Family history of VHL
• Positive for the familial mutation in exon 3 of the VHL 
gene
• Commenced screening programme 









o Right renal carcinoma 28yrs











o Cervical spine 
haemangioblastoma 33yrs
o Bilateral renal cell carcinomas 
34 7 35yrs
• Half-brother
o Right phaechromocytoma age 
14yrs







o Lesion seen on abdominal MRI
o Repeat MRI with contrast
o MIBG scan




o Urine catecholamine 
(noradrenaline) slightly elevated
• 370nmol/day (N=below 194)









• Review of imaging  for endocrine VHL MDT 31.10.2012
• There is a 3cm MIBG positive paraganglioma in the upper 
retroperitoneum interposed between in the aorta, IVC and 
portal vein. No local invasion seen. Slow increase in size since 
2008.
• Small areas of soft tissue in the distal aorto-caval region but 
these are currently indeterminate.
• Normal kidneys, adrenals and pancreas






• No plans for surgery
• Intermittent symptoms and continued raised catecholamines
• Commence Doxazocin 0.5mg once daily
o Increase to twice a day after a week if tolerated





• New 9mm peripherally enhancing left adrenal 
nodule which demonstrates restricted diffusion likely 




o November age 13yrs
• Now wants to be seen without his Mum
• ? Phaeochromocytoma
• Tom very stressed and upset




• The anterior lesion in the tail of the pancreas is still 
present and demonstrates an arterial blush. 
• This remains suggestive of an islet cell tumour. 
• No other pancreatic lesion is demonstrated.

MRI adrenals 14.7.15
• The right adrenal mass in the body of the adrenal 
has further increased in size now measures 13 mm. 
• The left adrenal nodule in the lateral limb is stable 
measuring 15 mm.
• Both lesions have similar properties and the 








o Now proceed to surgery
o December had surgery
• 2016
o April – surgical follow up
o As you know he underwent a right laparoscopic adrenalectomy for a 
pheochromocytoma within the Von Hippel Lindau syndrome in December last year, 
from which he made a rapid and uncomplicated post-operative recovery.
o On examination today, all incisions have healed well.
o We knew pre-operatively that he had bilateral phaeochromocytomas however the 
right was the largest and we hoped to proceed with a staged adrenalectomy to 
preserve adrenal function for as long as possible.  
o Unfortunately, post-operative urinary nor-metadrenaline has not decreased 
substantially although his mother tells me he remains normotensive and 
asymptomatic.
o I discussed the findings with him and his mother today and I have suggested that he 
seeks an early appointment with the paediatric endocrine team to discuss the 
potential for going back on to doxazosin.  He particularly would like to avoid further 








• Management of children with NETs very complex
• Importance of screening emphasised
o Genetics and clinical
• Inform families
• Reduce need for screening
• Reduction in morbidity compared to their parents
• Can screen from age 5yrs
o MEN2b genetics from age 1yr
• Potentials for further management
o Nursery / School
• Hydrocortisone management
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